Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Tudriqev |
|---|---|
| Manufacturer | Replimune, In |
| Prescription required | Yes |
Tudriqev 106 PFU/mlinjection 1vial x 1ml(vusolimogene oderparepvec-wtpg)
vusolimogene oderparepvec-wtpg
Description
Tudriqev 106 PFU/mlinjection 1vial x 1ml(vusolimogene oderparepvec-wtpg) is a medicine catalog record in the MediPriceHub database. Active ingredient: vusolimogene oderparepvec-wtpg. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Replimune, In. Therapeutic category: Medicine Library > Oncology Medicines > Melanoma Medicines. Pack information: 106 PFU /, 1 x 1. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response [ see Clinical Studies ]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).How to Use
Use vusolimogene oderparepvec-wtpg under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: vusolimogene oderparepvec-wtpg. Pack size: 106 PFU /, 1 x 1. Pack unit: unit. Manufacturer: Replimune, In. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Melanoma Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Ces informations sont fournies à titre indicatif. Demandez conseil à un professionnel de santé avant d'utiliser un médicament.